322 related articles for article (PubMed ID: 21668337)
21. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
22. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
23. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
24. Insulin detemir: A historical perspective on a modern basal insulin analogue.
Meneghini L; Liebl A; Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S31-42. PubMed ID: 20394890
[TBL] [Abstract][Full Text] [Related]
25. [New methods in insulin treatment].
Neuwirth G
Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
[TBL] [Abstract][Full Text] [Related]
26. Addressing hyperglycemia from hospital admission to discharge.
Moghissi ES
Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
[TBL] [Abstract][Full Text] [Related]
27. Insulin detemir, does a new century bring a better basal insulin?
Hordern SV; Russell-Jones DL
Int J Clin Pract; 2005 Jun; 59(6):730-9. PubMed ID: 15924603
[TBL] [Abstract][Full Text] [Related]
28. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats.
Marshall RD; Rand JS; Morton JM
J Vet Pharmacol Ther; 2008 Jun; 31(3):205-12. PubMed ID: 18471141
[TBL] [Abstract][Full Text] [Related]
29. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
30. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
31. Insulin glargine: a new basal insulin.
Levien TL; Baker DE; White JR; Campbell RK
Ann Pharmacother; 2002 Jun; 36(6):1019-27. PubMed ID: 12022906
[TBL] [Abstract][Full Text] [Related]
32. The evolution of insulin glargine and its continuing contribution to diabetes care.
Hilgenfeld R; Seipke G; Berchtold H; Owens DR
Drugs; 2014 Jun; 74(8):911-27. PubMed ID: 24866023
[TBL] [Abstract][Full Text] [Related]
33. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
34. Effect of lente insulin for treatment of diabetes mellitus in 12 cats.
Bertoy EH; Nelson RW; Feldman EC
J Am Vet Med Assoc; 1995 Jun; 206(11):1729-31. PubMed ID: 7782245
[TBL] [Abstract][Full Text] [Related]
35. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
Mathur SK; Bansal A; Khan ZY
J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
[TBL] [Abstract][Full Text] [Related]
36. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
[TBL] [Abstract][Full Text] [Related]
37. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
38. The evolution of insulin therapy in diabetes mellitus.
Heile M; Schneider D
J Fam Pract; 2012 May; 61(5 Suppl):S6-12. PubMed ID: 22577636
[No Abstract] [Full Text] [Related]
39. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
Heise T; Mathieu C
Diabetes Obes Metab; 2017 Jan; 19(1):3-12. PubMed ID: 27593206
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic compliance and flexibility in the use of basal insulins].
Costa Gil JE; Litwak LE; Fuente GV; Faingold MC
Medicina (B Aires); 2014; 74(4):273-81. PubMed ID: 25188652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
